**[338] V-WAVE: UNIDIRECTIONAL INTERATRIAL SHUNTING FOR THE MANAGEMENT OF HEART FAILURE**

**Erez Rozenfeld1, Sergio Shkurovich1, Neal Eigler1, 1 V-Wave Ltd;**

* **Investment Rationale:**

V-Wave makes implantable atrial shunt devices for improving patient outcomes in heart failure (HF). With one-million hospitalizations for worsening HF in the US alone, there are large and growing clinical needs and market opportunities. V-Wave recently closed a $28M round B financing and has an experienced management team with a proven track record in Class III cardiovascular devices.

* **Business Strategy:**

V-Wave is conducting early clinical trials in Canada, Europe and Israel, which show promising results for safety and effectiveness. The company is planning a larger and longer duration prospective, randomized, double blind, sham controlled pivotal trial with US and international sites. This experience will support regulatory applications and reimbursement of V-Wave’s technology in key markets around the world.

* **Core Technology:**

V-Wave is designing a unidirectional interatrial shunt that regulates left atrial pressure. The design of the shunt allows for a simple percutaneous implantation performed in the cardiac catheterization lab in under one hour. The shunt includes a tissue valve which prevents retrograde flow and reduces the risk of thrombus going into the left circulation.

* **Product Profile/Pipeline:**

V-Wave is developing a suite of patented shunts and delivery system technologies, while in parallel, pursuing the ultimate commercialization of its products. Strategic investors, Edwards Lifesciences and Johnson and Johnson are collaborating with V-Wave in several areas. V-Wave will be seeking additional funds to supports its operational plan and especially the pivotal trial of its shunt technology.

* **What's Next?**

The V-Wave shunt has been implanted successfully in all 38 subjects attempted and will continue to be used in clinical studies leading to regulatory approvals. With V-Wave’s world-class Scientific and Advisory Board and trial investigators and the backing of respected VC Firms and Strategic Investors, V-Wave is well poised to address a multibillion dollar opportunity in the HF space.